Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa

References

• Feng W, Sun F, Wang Q, et al. Epidemiology and resistance characteristics of Pseudomonas aeruginosa isolates from the respiratory department of a hospital in China. J Glob Antimicrob Resist. 2017;8:142–147.
   PubMed Web of Science ®Google Scholar
• Cai Y, Yang D, Wang J, et al. Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model. J Antimicrob Chemother. 2018;73(2):456–461.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, de Jonge BLM, Stone GG, et al. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018;73(10):2777–2781.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Croxatto A, et al. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527.
   PubMedGoogle Scholar
• Tschudin-Sutter S, Fosse N, Frei R, et al. Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections. PLoS One. 2018;13(9):e0203295.
   PubMed Web of Science ®Google Scholar
• Wong D, van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615–628.
   PubMed Web of Science ®Google Scholar
• Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016; 63(2):234–241.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 30th ed. Wayne, Pennsylvania: CLSI supplement M100 Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents- Approved Guideline M26 A. Wayne NCCLS, 1999.
   Google Scholar
• Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis. 2017;62:39–43.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Stone GG, Sader HS, et al. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother. 2014;26(6):333–338.
   PubMed Web of Science ®Google Scholar
• Li H, Estabrook M, Jacoby GA, et al. In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59(3):1789–1793.
   PubMed Web of Science ®Google Scholar
• Yadav R, Bulitta JB, Nation RL, et al. Optimization of synergistic combination regimens against carbapenem-and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamics modeling. Antimicrob Agents Chemother. 2017;61(1):e01011–e01016.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Bulitta JB, Forrest A, et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;54(9):3783–3789.
   PubMed Web of Science ®Google Scholar
• Johansen HK, Moskowitz SM, Ciofu O, et al. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros. 2008;7(5):391–397.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Forrest A, Bulitta JB, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother. 2011;55(11):5134–5142.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(12):5685–5695.
   PubMed Web of Science ®Google Scholar
• Tängdén T, Karvanen M, Friberg LE, et al. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infect Dis (Lond)). 2017;49(7):521–527.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Zissis NP, Tagari G, et al. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984;25(4):534–536.
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med. 1986;80(6B):126–137.
   PubMed Web of Science ®Google Scholar
• Sande MA, Johnson ML. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis. 1975;131(4):367–375.
   PubMed Web of Science ®Google Scholar
• Moellering RS. Principles of anti infective therapy. In: Mandell GL, Bennet JE, Dolin R, editors. Mandell, Douglas, and Bennet’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000.
   Google Scholar
• Sun HY, Fujitani S, Quintiliani R, et al. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest. 2011;139(5):1172–1185.
   PubMed Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America [published correction appears in Circulation. 2005 Oct 11;112(15):2373] [published correction appears in Circulation. 2007 Apr 17;115(15):e408] [published correction appears in Circulation. 2007 Nov 20;116(21):e547] [published correction appears in Circulation.2008 Sep 16;118(12):e497]. Circulation. 2005;111(23):e394–e434.
   PubMed Web of Science ®Google Scholar
• Paul M, Lador A, Grozinsky-Glasberg S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;7(1):CD003344.
   Google Scholar
• Grillon A, Schramm F, Kleinberg M, et al. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. PLoS One. 2016;11(6):e0156690.
   PubMed Web of Science ®Google Scholar
• Safarika A, Galani I, Pistiki A, et al. Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2015;34(2):317–323.
   PubMed Web of Science ®Google Scholar
• Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother. 2002;50(6):1045–1049.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Deshpande LM, Costello A, et al. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J Antimicrob Chemother. 2014;69(7):1804–1814.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diag Microb Infect Dis. 2009;63(4):426–433.
   PubMed Web of Science ®Google Scholar
• Riera E, Cabot G, Mulet X, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother. 2011;66(9):2022–2027.
   PubMed Web of Science ®Google Scholar
• Luyt CE, Aubry A, Lu Q, et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1372–1380.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lewis RE, Volpe SL, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3.
   PubMed Web of Science ®Google Scholar